Valeant Pharmaceuticals Completes Bond Offering
February 8, 2011
Cahill represented the initial purchasers in a Rule 144A/Reg S Offering of $650 million of 6.750% Senior Notes due 2021 by Valeant Pharmaceuticals International. Valeant intends to use the net proceeds from the offering of the Notes to finance acquisitions and for general corporate purposes.
